DK2931042T3 - Anthracyclinformuleringer - Google Patents

Anthracyclinformuleringer Download PDF

Info

Publication number
DK2931042T3
DK2931042T3 DK13863251.8T DK13863251T DK2931042T3 DK 2931042 T3 DK2931042 T3 DK 2931042T3 DK 13863251 T DK13863251 T DK 13863251T DK 2931042 T3 DK2931042 T3 DK 2931042T3
Authority
DK
Denmark
Prior art keywords
anthracycline
formulations
anthracycline formulations
Prior art date
Application number
DK13863251.8T
Other languages
English (en)
Inventor
Scott Geyer
Daniel Levitt
Carrie Nodgaard
Edward H Trappler
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Application granted granted Critical
Publication of DK2931042T3 publication Critical patent/DK2931042T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK13863251.8T 2012-12-13 2013-12-13 Anthracyclinformuleringer DK2931042T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737003P 2012-12-13 2012-12-13
PCT/US2013/075002 WO2014093815A1 (en) 2012-12-13 2013-12-13 Anthracycline formulations

Publications (1)

Publication Number Publication Date
DK2931042T3 true DK2931042T3 (da) 2021-06-07

Family

ID=50934989

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13863251.8T DK2931042T3 (da) 2012-12-13 2013-12-13 Anthracyclinformuleringer

Country Status (8)

Country Link
US (2) US20150342975A1 (da)
EP (2) EP3915369A1 (da)
JP (5) JP6433913B2 (da)
AU (1) AU2013359048A1 (da)
CA (1) CA2894548C (da)
DK (1) DK2931042T3 (da)
HK (1) HK1209973A1 (da)
WO (1) WO2014093815A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915369A1 (en) * 2012-12-13 2021-12-01 CytRx Corporation Anthracycline formulations
JP2016521705A (ja) 2013-06-05 2016-07-25 サイトレックス コーポレイション がんを処置するための細胞傷害剤
BR112018003631A2 (pt) 2015-08-25 2018-09-25 Nantomics Llc sistemas e métodos para busca por variante de alta precisão
US11071812B2 (en) * 2016-05-31 2021-07-27 Penumbra, Inc. Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood
AU2018318125B2 (en) 2017-08-15 2021-09-09 Nantcell, Inc. Hank cetuximab combinations and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
JP2915252B2 (ja) 1993-06-30 1999-07-05 明治製菓株式会社 溶解性が改善された製剤の製造法
ES2285743T3 (es) * 1996-12-30 2007-11-16 Battelle Memorial Institute Uso de un farmaco anticancerigeno no encapsulado para la preparacion de una formulacion para tratar neoplasias mediante inhlacion.
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ,インコーポレーティッド. パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
BRPI0811248A2 (pt) * 2007-05-16 2014-11-04 Ktb Tumorforschungs Gmbh Formulação de antraciclina de baixa viscosidade.
EP2216049A1 (en) * 2009-02-06 2010-08-11 Freie Universität Berlin Drug conjugates with polyglycerols
EP2346896A4 (en) * 2008-10-15 2014-06-25 Angiochem Inc CONJUGATES OF ETOPOSIDE AND DOXORUBICIN FOR THE ADMINISTRATION OF MEDICAMENTS
EP3915369A1 (en) * 2012-12-13 2021-12-01 CytRx Corporation Anthracycline formulations

Also Published As

Publication number Publication date
US20170340655A1 (en) 2017-11-30
US10328093B2 (en) 2019-06-25
JP2021120415A (ja) 2021-08-19
EP2931042B1 (en) 2021-04-28
CA2894548A1 (en) 2014-06-19
HK1209973A1 (en) 2016-04-15
CA2894548C (en) 2021-01-12
JP2018165280A (ja) 2018-10-25
JP6433913B2 (ja) 2018-12-05
JP6833768B2 (ja) 2021-02-24
EP2931042A4 (en) 2016-06-01
JP7213303B2 (ja) 2023-01-26
EP2931042A1 (en) 2015-10-21
US20150342975A1 (en) 2015-12-03
JP2021120414A (ja) 2021-08-19
EP3915369A1 (en) 2021-12-01
WO2014093815A1 (en) 2014-06-19
AU2013359048A1 (en) 2015-07-02
JP2016503026A (ja) 2016-02-01
JP2019206583A (ja) 2019-12-05

Similar Documents

Publication Publication Date Title
FR23C1020I2 (fr) Conjugues pyrrolobenzodiazepine-anticorps
DK2906251T3 (da) Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
BR112015008232A2 (pt) conjugados pirrolbenzodiazepina-anticorpo
DK3725778T3 (da) Formuleringer af enzalutamid
DK2920304T3 (da) Oligonukleotidkonjugater
CO6801645A2 (es) Nuevos inmunoconjugados
DK3117837T3 (da) Antistofformuleringer
ES2969363T3 (es) Formulaciones
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
BR112014032798A2 (pt) composição
DK2825157T3 (da) Aminosyrelipider
DK2831122T3 (da) Anthocyanidin-kompleks
HK1209973A1 (en) Anthracycline formulations
BR112014032712A2 (pt) composição
DE112012006214T8 (de) Wulstringwickler
DE112012005566T8 (de) Seltenerdnanoverbundmagnet
DK2672817T3 (da) Forbedrede insekticide formuleringer
DK2885638T3 (da) Molekylenet
DK2858657T3 (da) Feijoafrugtekstrakt
DK2811828T3 (da) Adjuvanssammensætninger